$RLFTF Various DD (copied) FDA grants inhaled use IND

New Post Public Reply Private Reply Replies (0) Message Board
mc67
837
$RLFTF Various DD (copied)

FDA grants inhaled use IND for RLF-100 (aviptadil) to treat patients with moderate and severe COVID-19 aiming to prevent progression to respiratory failure


- Aviptadil is now shown as the first COVID therapeutic to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while also preventing synthesis of cytokines in the lung

- RLF-100 is a patented formulation of aviptadil (synthetic human Vasoactive Intestinal Polypeptide, VIP), which has been granted FDA Fast Track Designation, FDA emergency use IND authorization, and an expanded access protocol.

RADNOR, Pa. and GENEVA,
Aug. 6, 2020 /PRNewswire/ -- NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF, OTC:RLFTF) "Relief" today announced that NeuroRx has been granted Investigational New Drug (IND) permission to test RLF-100 (aviptadil) for inhaled use in patients with moderate and severe COVID-19 in order to prevent progression to respiratory failure.

The study is posted at https://clinicaltrials.gov/ct2/show/NCT04360096. The first phase will commence with patients hospitalized for severe COVID-19 who do not yet have respiratory failure. If promising results are seen in the inpatient setting, the trial will expand to patients at home with mild and moderate COVID-19 in order to prevent the need for hospital admission.

Professor Jonathan Javitt, MD, MPH, CEO of NeuroRx said, "Now that we know VIP suppresses replication of the SARS-CoV-2 virus in human lung cells, based on the outstanding work of the Oswaldo Cruz Institute (Rio de Janeiro).1 We are optimistic that treatment with VIP will not only help patients on ventilators, but will help to stop the advancement of the virus in patients with earlier stages of COVID-19. By blocking cytokine synthesis in the lung cells and increasing the production of surfactant, which is key to the lung's ability to transmit oxygen, we are hopeful that inhaled VIP will prove to be of clinical benefit across a wider array of patients suffering respiratory complications from COVID-19 infection."

The clinical trial of the inhaled formulation of RLF-100 is expected to begin on or before September 1, 2020.

About VIP in Lung Injury

Vasoactive Intestinal Polypeptide (VIP) was first discovered by the late Dr. Sami Said in 1970. Although first identified in the intestinal tract, VIP is now known to be produced throughout the body and to be primarily concentrated in the lungs. VIP has been shown in more than 100 peer-reviewed studies to have potent anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury, and inflammation. Most importantly, 70% of the VIP in the body is bound to a rare cell in the lung, the Alveolar Type II cell, which is critical for the transmission of oxygen to the body. VIP has a 20-year history of safe use in humans in multiple human trials for sarcoidosis, pulmonary fibrosis, asthma/allergy, and pulmonary hypertension.

COVID-19-related death is primarily caused by respiratory failure. Before this acute phase, however, there is evidence of early viral infection of the alveolar type 2 cells. These cells are known to have angiotensin converting enzyme 2 (ACE2) receptors at high levels, which serve as the route of entry for the SARS-CoV-2 into the cells. Coronaviruses are shown to replicate in alveolar type 2 cells, but not in the more numerous type 1 cells. These same type 2 alveolar cells have high concentrations of VIP receptors on their cell surfaces giving rise to the hypothesis that VIP could specifically protect these cells from injury.

Injury to the type 2 alveolar cells is an increasingly plausible mechanism of COVID-19 disease progression (Mason 2020). These specialized cells replenish the more common type 1 cells that line the lungs. More importantly, type 2 cells manufacture surfactant that coats the lung and is essential for oxygen exchange. Other than RLF-100, no currently proposed treatments for COVID-19 specifically target these vulnerable type 2 cells.

About RLF-100

RLF-100 (aviptadil) is a patented formulation of Vasoactive Intestinal Polypeptide (VIP) that was developed based on Dr. Said's original work and was originally approved for human trials by the FDA in 2001 and the European Medicines Agency in 2005. VIP is known to be highly concentrated in the lungs and to inhibit a variety of inflammatory cytokines. Relief's predecessor company, Mondo Biotech, was awarded Orphan Drug Designation in 2001 by the U.S. FDA for aviptadil in the treatment of Acute Respiratory Distress Syndrome and in 2005 for treatment of Pulmonary Arterial Hypertension. Mondo was awarded Orphan Drug Designation by the European Medicines Agency in 2006 for the treatment of acute lung injury and in 2007 for the treatment of sarcoidosis. Both Mondo and Relief have worked on development of an inhaled formulation of aviptadil for several years. Both the U.S. FDA and the EMEA have granted Investigational New Drug licenses for human trials of aviptadil.

About RELIEF THERAPEUTICS Holding AG

The Relief group of companies focus primarily on clinical-stage projects based on molecules of natural origin (peptides and proteins) with a history of clinical testing and use in human patients or a strong scientific rationale. Currently, Relief is concentrating its efforts on developing new treatments for respiratory disease indications.

Relief Therapeutics holds orphan drug designations from the U.S. Food and Drug Administration and the European Union for the use of VIP to treat ARDS, pulmonary hypertension, and sarcoidosis. Relief Therapeutics also holds a U.S. patent (US8178489 formulation for aviptadil) for RLF-100 and proprietary manufacturing processes for its synthesis.

RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF.

About NeuroRx, Inc.

NeuroRx draws upon more than 100 years of collective drug development experience and is led by former senior executives of Johnson & Johnson, Eli Lilly, Pfizer, and AstraZeneca, PPD. In addition to its work on RLF-100, NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 for the treatment of suicidal bipolar depression and is currently in Phase 3 trials. Its Board of Directors and Advisors includes Hon. Sherry Glied, former Assistant Secretary, U.S. Dept. of Health and Human Services; Mr. Chaim Hurvitz, former President of the Teva International Group, Lt. Gen. HR McMaster, the 23rd National Security Advisor, Wayne Pines, former Associate Commissioner of the U.S. Food and Drug Administration, Judge Abraham Sofaer, and Daniel Troy, former Chief Counsel, U.S. Food and Drug Administration.

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG, NeuroRx, Inc. and their businesses. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG and/or NeuroRx, Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

CORPORATE CONTACTS

US Inquiries
Jonathan C. Javitt, M.D., MPH
Chief Executive Officer
NeuroRx, Inc.
ceo@neurorxpharma.com

Europe Inquiries
Yves Sagot, Ph.D.
Chief Scientific Officer
Relief Therapeutics Holding AG
yves.sagot@relieftherapeutics.com

MEDIA CONTACT

US - David Schull
Russo Partners, LLC
david.schull@russopartnersllc.com
858-717-2310

Europe - Raimund Gabriel, Laurie Doyle
MC Services AG
Neurorx@mc-services.eu
+49 89 210 228 0

INVESTOR RELATIONS

Brian Korb
Solebury Trout
bkorb@troutgroup.com
917-653-5122

1

Temerozo JR, Sacramenta Q, Fintelman-Rodriques N, et. al. The neuropeptides VIP and PACAP inhibit SARS-CoV-2 replication in monocytes and lung epithelial cells, decrease the production of proinflammatory cytokines, and VIP levels are associated with survival in severe Covid-19 patients doi: https://doi.org/10.1101/2020.07.25.220806. https://www.biorxiv.org/content/10.1101/2020....806v2.full



https://c212.net/c/img/favicon.png?sn=NY84514...2020-08-06 View original content:http://www.prnewswire.com/news-releases/fda-grants-inhaled-use-ind-for-rlf-100-aviptadil-to-treat-patients-with-moderate-and-severe-covid-19-aiming-to-prevent-progression-to-respiratory-failure-301107288.html

SOURCE NeuroRx, Inc; Relief Therapeutics Holding AG

https://www.otcmarkets.com/stock/RLFTF/news/s...id=1663433


----

Life Saving RLF-100

https://arizonadailyindependent.com/valley-hu...-covid-19/

----

Fox News link! https://video.foxbusiness.com/v/6178856365001/#sp=show-clips

---


Awesome find Andy2018

A few excerpts from comments by the Chairman

On safety of the drug

Quote:
The active pharmaceutical ingredient of Aviptadil has been used for a lot of years in different indications. From a safety standpoint we are quite optimistic.


On the efficacy of the drug

Quote:
It is very challenging to treat this disease and rare to identify a therapy that actually can have an impact...There is now first evidence that Relief's drug is working...the fact that we have been fortunate enough to move a clinical program ahead very quickly: We have now started to see evidence that the drug is working. Many other people have tried things in Covid-19 and didn't get very far...I would say the probability at the moment stands at 60 to 70% that we will get the drug approved.


On financing

Quote:
There are effectively two trials: For the one we are currently running the total budget will be in the range of CHF 7 to 8 mio. The Inhaled study we just got approval to start will probably cost between CHF 10 and 15 mio....We have access to a share subscription facility from which we can draw...We have already spent close to CHF 4 mio. on the trials, and we currently have close to CHF 3 mio.


on Top-line results

Quote:
it would only take us a few more months to get to the point where we would be able to report top-line results from this trial.


On revenues

Quote:
it could generate hundreds of millions of dollars per year during that timeframe...Aviptadil is our drug...That is the current situation.


A 60% 70% probability of approval is pretty high. I wonder if any other CEOs of the Covid-19 companies have said or can say this. I've not personally seen. Upon approval, sky is the limit for pps. I also believe our CEO is being cautious and conservative.

https://themarket.ch/interview/relief-therape...ar-ld.2478

$RLFTF

Disclaimer: Just my opinion of course, do your ow DD.




mikar : "No other antiviral agent has demonstrated rapid recovery from viral infection and demonstrated laboratory inhibition of viral replication," said Prof. Jonathan Javitt, CEO and Chairman of NeuroRx. "We are conducting placebo-controlled trials to see whether the observations made in the case-control and open-label studies will be confirmed for less ill patients with COVID-19-related respiratory failure. Our independent Data Monitoring Committee will be conducting an interim analysis of these data later this month."



Agreed again. Read here:

Quote:
Independent research has found RFL-100 can block COVID-19's replication in human lung cells and monocytes; no other antiviral agent has demonstrated rapid recovery from viral infection and demonstrated laboratory inhibition of viral replication, says Jonathan Javitt, CEO, NeuroRx


https://www.businesstoday.in/coronavirus/coro...12306.html

RLFTF

Imho only

Mondobiotech Holding AG Basel (RLFTF) Stock Research Links

RLFTF Board Company Profile Buy Rating Time & Sales News Filings Financials
$MJ
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 209

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 258

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 195

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 176

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 150

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 126

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 118

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 215

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 112

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 154

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Future of Hydrogen Detection Technology and Growth

Updated Category News Views 545

Hydrogen Detection Market Size & Growth Insights The hydrogen detection market is on a remarkable trajectory, aiming to reach an impressive USD 642.39 million by 2032. This growth represents a substantial compound annual growth rate (CAGR) of 11.89% from 2024 to 2032, starting with a market valuation of USD 234.9 million in 2023. The ongoing emphasis on hydrogen as a...

Continue Reading
Insights into Novonesis’ Share Buyback Program Transactions

Updated Category News Views 336

Understanding Novonesis’ Share Buyback Program The financial landscape continuously evolves, and one significant strategy that companies often utilize is a share buyback program. Novonesis is currently engaging in such a strategy, which has piqued the interest of many investors and market analysts alike. This program allows a company to repurchase its shares from the...

Continue Reading
Discover Chippewa Boots' Newest October Selection for Workers

Updated Category News Views 250

October Boot of the Month: The Paladin and Tinsley Chippewa Boots proudly presents its October Boot of the Month: the Paladin and Tinsley, both exceptional 8-inch Waterproof Insulated Steel Toe Loggers. These boots are designed to excel in tough work environments while providing the necessary protection, comfort, and performance that professionals need. Features of the...

Continue Reading
Understanding Broadcom's Recent Options Activity and Insights

Updated Category News Views 100

Broadcom's Options Activity: What Investors Are Observing Investors with considerable capital are showing a notable interest in Broadcom (NASDAQ: AVGO), currently adopting a more cautious stance than usual. This trend is captured through significant options activity that market players should closely monitor. While the identities of these investors remain undisclosed, the...

Continue Reading
Santa Clara University Celebrates Diverse Class of 2028

Updated Category News Views 597

Welcoming a New Era at Santa Clara University Santa Clara University has kicked off a new chapter with over 1,800 enthusiastic undergraduates joining the ranks during a lively Welcome Weekend. This event was not just about filling seats; it was a whirlwind of social gatherings—from dance parties to heartfelt ceremonies—showing SCU’s determination to cultivate an...

Continue Reading